The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Psoriasis pathogenesis and the development of novel targeted immune therapies
Open accessAbstract
&NA; Psoriasis is caused by a complex interplay between the immune system, psoriasis‐associated susceptibility loci, autoantigens, and multiple environmental factors. Over the last 2 decades, research has unequivocally shown that psoriasis represents a bona fide T cell–mediated disease primarily driven by pathogenic T cells that produce high levels of IL‐17 in response to IL‐23. The discovery of the central role for the IL‐23/type 17 T‐cell axis in the development of psoriasis has led to a major paradigm shift in the pathogenic model for this condition. The activation and upregulation of IL‐17 in prepsoriatic skin produces a “feed forward” inflammatory response in keratinocytes that is self‐amplifying and drives the development of mature psoriatic plaques by inducing epidermal hyperplasia, epidermal cell proliferation, and recruitment of leukocyte subsets into the skin. Clinical trial data for mAbs against IL‐17 signaling (secukinumab, ixekizumab, and brodalumab) and newer IL‐23p19 antagonists (tildrakizumab, guselkumab, and risankizumab) underscore the central role of these cytokines as predominant drivers of psoriatic disease. Currently, we are witnessing a translational revolution in the treatment and management of psoriasis. Emerging bispecific antibodies offer the potential for even better disease control, whereas small‐molecule drugs offer future alternatives to the use of biologics and less costly long‐term disease management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antimicrobial peptides of multicellular organisms
Zasloff, M. (2002) · Nature · doi:10.1038/415389a · Cited by 8,457
Korn, T., Bettelli, E., Oukka, M., & Kuchroo, V. K. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132710 · Cited by 4,873
Nestle, F. O., Kaplan, D. H., & Barker, J. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804595 · Cited by 2,786
Secukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997
Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide
Lande, R., Gregorio, J., Facchinetti, V., Chatterjee, B., Wang, Y.-H., Homey, B., Cao, W., Wang, Y.-H., Su, B., Nestle, F. O., et al. (2007) · Nature · doi:10.1038/nature06116 · Cited by 1,910
Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis
Zheng, Y., Danilenko, D. M., Valdez, P., Kasman, I., Eastham-Anderson, J., Wu, J., & Ouyang, W. (2007) · Nature · doi:10.1038/nature05505 · Cited by 1,862
Lowes, M. A., Suárez-Fariñas, M., & Krueger, J. G. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120225 · Cited by 1,650
Self-citationPsoriasis causes as much disability as other major medical diseases
Rapp, S. R., Feldman, S. R., Exum, M. L., Fleischer, A. B., & Reboussin, D. M. (1999) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(99)70112-x · Cited by 1,491
Generation of pathogenic TH17 cells in the absence of TGF-β signalling
Ghoreschi, K., Laurence, A., Yang, X.-P., Tato, C. M., McGeachy, M. J., Konkel, J. E., Ramos, H. L., Wei, L., Davidson, T. S., Bouladoux, N., et al. (2010) · Nature · doi:10.1038/nature09447 · Cited by 1,388
Psoriasis and comorbid diseases
Takeshita, J., Grewal, S., Langan, S. M., Mehta, N. N., Ogdie, A., Van Voorhees, A. S., & Gelfand, J. M. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.07.064 · Cited by 1,145
Cited by
Griffiths, C. E. M., Armstrong, A. W., Gudjonsson, J. E., & Barker, J. N. W. N. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32549-6 · Cited by 2,383
Advances in the pathogenesis of psoriasis: from keratinocyte perspective
Zhou, X., Chen, Y., Cui, L., Shi, Y., & Guo, C. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-04523-3 · Cited by 632
Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis
Hawkes, J. E., Yan, B. Y., Chan, T. C., & Krueger, J. G. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800013 · Cited by 593
Self-citationThe IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond
Brembilla, N. C., Senra, L., & Boehncke, W.-H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01682 · Cited by 475
The IL-17 family in diseases: from bench to bedside
Huangfu, L., Li, R., Huang, Y., & Wang, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01620-3 · Cited by 452
The Interplay Between Keratinocytes and Immune Cells in the Pathogenesis of Psoriasis
Albanesi, C., Madonna, S., Gisondi, P., & Girolomoni, G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01549 · Cited by 432
Cytokinocytes: the diverse contribution of keratinocytes to immune responses in skin
Jiang, Y., Tsoi, L. C., Billi, A. C., Ward, N. L., Harms, P. W., Zeng, C., Maverakis, E., Kahlenberg, J. M., & Gudjonsson, J. E. (2020) · JCI Insight · doi:10.1172/jci.insight.142067 · Cited by 348
Immune-mediated inflammatory disease therapeutics: past, present and future
McInnes, I. B., & Gravallese, E. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00603-1 · Cited by 337
Deodhar, A., Gensler, L. S., Sieper, J., Clark, M., Calderon, C., Wang, Y., Zhou, Y., Leu, J. H., Campbell, K., Sweet, K., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40728 · Cited by 334
Interleukin-17A and Keratinocytes in Psoriasis
Furue, M., Furue, K., Tsuji, G., & Nakahara, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041275 · Cited by 300
New Treatment Addressing the Pathogenesis of Psoriasis
Tokuyama, M., & Mabuchi, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207488 · Cited by 291
Ma, F., Plazyo, O., Billi, A. C., Tsoi, L. C., Xing, X., Wasikowski, R., Gharaee-Kermani, M., Hile, G., Jiang, Y., Harms, P. W., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39020-4 · Cited by 284
Sparber, F., De Gregorio, C., Steckholzer, S., Ferreira, F. M., Dolowschiak, T., Ruchti, F., Kirchner, F. R., Mertens, S., Prinz, I., Joller, N., et al. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.02.002 · Cited by 255
Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis
Ungar, B., Pavel, A. B., Li, R., Kimmel, G., Nia, J., Hashim, P., Kim, H. J., Chima, M., Vekaria, A. S., Estrada, Y., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.04.055 · Cited by 119
Local heroes or villains: tissue-resident memory T cells in human health and disease
Sasson, S. C., Gordon, C. L., Christo, S. N., Klenerman, P., & Mackay, L. K. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0359-1 · Cited by 111
Crosstalk: keratinocytes and immune cells in psoriasis
Kamata, M., & Tada, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1286344 · Cited by 110
Psoriasis and Systemic Inflammatory Disorders
Tashiro, T., & Sawada, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084457 · Cited by 104
Tomalin, L. E., Kim, J., Correa da Rosa, J., Lee, J., Fitz, L. J., Berstein, G., Valdez, H., Wolk, R., Krueger, J. G., & Suárez-Fariñas, M. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.09.023 · Cited by 46
Self-citationZareie, P., Weiss, E. S., Kaplan, D. H., & Mackay, L. K. (2025) · Nature Immunology · doi:10.1038/s41590-025-02145-3 · Cited by 29
Wang, M., Li, T., Ouyang, Z., Tang, K., Zhu, Y., Song, C., Sun, H., Yu, B., Ji, X., & Sun, Y. (2022) · iScience · doi:10.1016/j.isci.2022.104009 · Cited by 20
Florian, P., Flechsenhar, K. R., Bartnik, E., Ding‐Pfennigdorff, D., Herrmann, M., Bryce, P. J., & Nestle, F. O. (2020) · Experimental Dermatology · doi:10.1111/exd.13942 · Cited by 20
Endoplasmic reticulum stress links psoriasis vulgaris with keratinocyte inflammation
Zhao, M., Luo, J., Xiao, B., Tang, H., Song, F., Ding, X., & Yang, G. (2020) · Advances in Dermatology and Allergology · doi:10.5114/ada.2020.93382 · Cited by 18
“The recent advances in the understanding of psoriasis pathogenesis have directly led to the development of highly effective therapeutic targets, such as against IL-17 and IL-23 [4].”
BackgroundMa, Y., Liu, Y., Zhong, Y., Li, X., Xu, Y., Chen, L., Gong, L., Huang, H., Chen, X., He, Y., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17349 · Cited by 14
Artificial intelligence–enabled precision medicine for inflammatory skin diseases
Tang, A. S., Wei, M. L., Haemel, A., La, C., Sirota, M., & Lee, E. Y. (2026) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2025.10.596 · Cited by 10
Zhou, X., Ning, J., Cai, R., Liu, J., Yang, H., & Bai, Y. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s492875 · Cited by 5
Chen, Y.-T., Li, Y.-L., Wu, C.-Y., Chen, L.-Y., & Chiou, H.-Y. (2025) · Asia Pacific Journal of Public Health · doi:10.1177/10105395251328405 · Cited by 3
Metadata
- Authors
- Hawkes, J. E., Chan, T. C., & Krueger, J. G.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 140
- Issue
- 3
- Pages
- 645-653
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2752721387
- Cited by
- 972
- References
- 79
- FWCI
- 30.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.